Market closed
EyePoint Pharmaceuticals/$EYPT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Ticker
$EYPT
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
165
ISIN
US30233G2093
Website
EYPT Metrics
BasicAdvanced
$420M
-
-$2.43
1.60
-
Price and volume
Market cap
$420M
Beta
1.6
52-week high
$13.42
52-week low
$3.91
Average daily volume
791K
Financial strength
Current ratio
7.846
Quick ratio
7.645
Long term debt to equity
7.478
Total debt to equity
8.137
Interest coverage (TTM)
-11,526.43%
Management effectiveness
Return on assets (TTM)
-29.16%
Return on equity (TTM)
-53.54%
Valuation
Price to revenue (TTM)
6.586
Price to book
1.43
Price to tangible book (TTM)
1.43
Growth
Revenue change (TTM)
12.04%
Earnings per share change (TTM)
31.44%
3-year revenue growth (CAGR)
12.93%
3-year earnings per share growth (CAGR)
4.85%
What the Analysts think about EYPT
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for EyePoint Pharmaceuticals stock.
EYPT Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
EYPT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
EYPT News
AllArticlesVideos
EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call Transcript
Seeking Alpha·2 days ago
EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025
GlobeNewsWire·1 week ago
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for EyePoint Pharmaceuticals stock?
EyePoint Pharmaceuticals (EYPT) has a market cap of $420M as of May 10, 2025.
What is the P/E ratio for EyePoint Pharmaceuticals stock?
The price to earnings (P/E) ratio for EyePoint Pharmaceuticals (EYPT) stock is 0 as of May 10, 2025.
Does EyePoint Pharmaceuticals stock pay dividends?
No, EyePoint Pharmaceuticals (EYPT) stock does not pay dividends to its shareholders as of May 10, 2025.
When is the next EyePoint Pharmaceuticals dividend payment date?
EyePoint Pharmaceuticals (EYPT) stock does not pay dividends to its shareholders.
What is the beta indicator for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals (EYPT) has a beta rating of 1.6. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.